Price Disclosure Reductions for 2023 April Cycle

Page last updated: 30 June 2023

The 2023 April cycle had a data collection period of 1 April 2022 to 30 September 2022.

Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 11 November 2022.

The reduction day was on 1 April 2023.

Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.

Contents

Outcomes of Price Disclosure calculations

The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes reflecting these determinations have been published in a legal determination on legal determination on the Federal Register of Legislation website in December 2022.  Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2022 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that was listed after 30 September 2022 also had the reduction on 1 April 2023 under section 99ADHA of the Act.

Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes was Friday, 13 January 2023.

A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.

Legal Instrument Drug

Legal Instrument Form

Legal Instrument MoA

Brands of PI designated brands under 99ADHC (Y/N)

Price reduction applied in 2 previous cycles (Y/N?)

Average UPR exceeds 12.5% over 3 cycles (Y/N)

Average AEMP

WAPD (%) (Drug/MoA)

Apr-23 AEMP

Oct-22 AEMP

Percentage difference between Apr-22 and Oct-22 AEMP (%)

UPR threshold (%)

Calculations based on:
OWAPD = all brand data
GWAPD = originator brand data removed
Does not meet 18/30 month clocks

acamprosate

Tablet (enteric coated) containing acamprosate calcium 333 mg

Oral

N

-

-

71.02

13.84%

61.19

71.02

13.84%

10%

GWAPD

ambrisentan

Tablet 10 mg

Oral

N

-

-

1,844.54

10.43%

1,652.15

1,844.54

10.43%

10%

Does not meet 18/30 month clocks

ambrisentan

Tablet 5 mg

Oral

N

-

-

1,844.54

10.43%

1,652.15

1,844.54

10.43%

10%

Does not meet 18/30 month clocks

baclofen

Intrathecal injection 40 mg in 20 mL

Injection

Y

N

Y

383.12

20.21%

305.69

383.12

20.21%

10%

GWAPD

bortezomib

Powder for injection 1 mg

Injection

N

-

-

172.91

24.83%

129.98

172.91

24.83%

10%

Does not meet 18/30 month clocks

bortezomib

Powder for injection 2.5 mg

Injection

N

-

-

432.28

24.83%

324.94

432.28

24.83%

10%

Does not meet 18/30 month clocks

bortezomib

Powder for injection 3 mg

Injection

N

-

-

518.72

24.83%

389.92

518.72

24.83%

10%

Does not meet 18/30 month clocks

bortezomib

Powder for injection 3.5 mg

Injection

N

-

-

605.17

24.83%

454.91

605.17

24.83%

10%

Does not meet 18/30 month clocks

bortezomib

Solution for injection 2.5 mg in 1 mL

Injection

N

-

-

432.28

24.83%

324.94

432.28

24.83%

10%

Does not meet 18/30 month clocks

bortezomib

Solution for injection 3.5 mg in 1.4 mL

Injection

N

-

-

605.17

24.83%

454.91

605.17

24.83%

10%

Does not meet 18/30 month clocks

buprenorphine

Transdermal patch 10 mg

Transdermal

N

-

-

17.29

10.67%

15.45

17.29

10.64%

10%

GWAPD

buprenorphine

Transdermal patch 15 mg

Transdermal

N

-

-

21.99

10.67%

19.64

21.99

10.69%

10%

GWAPD

buprenorphine

Transdermal patch 20 mg

Transdermal

N

-

-

26.69

10.67%

23.84

26.69

10.68%

10%

GWAPD

buprenorphine

Transdermal patch 25 mg

Transdermal

N

-

-

31.13

10.67%

27.81

31.13

10.66%

10%

GWAPD

buprenorphine

Transdermal patch 30 mg

Transdermal

N

-

-

35.58

10.67%

31.78

35.58

10.68%

10%

GWAPD

buprenorphine

Transdermal patch 40 mg

Transdermal

N

-

-

44.47

10.67%

39.73

44.47

10.66%

10%

GWAPD

buprenorphine

Transdermal patch 5 mg

Transdermal

N

-

-

9.60

10.67%

8.58

9.60

10.63%

10%

GWAPD

cabazitaxel

Concentrated injection 60 mg in 1.5 mL, with diluent

Injection

N

-

-

595.32

69.97%

178.77

304.57

41.30%

10%

Does not meet 18/30 month clocks

cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 3 mL

Injection

N

-

-

595.32

69.97%

178.77

304.57

41.30%

10%

Does not meet 18/30 month clocks

cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 6 mL

Injection

N

-

-

595.32

69.97%

178.77

304.57

41.30%

10%

Does not meet 18/30 month clocks

cinacalcet

Tablet 30 mg (as hydrochloride)

Oral

N

-

-

32.32

13.51%

27.95

32.32

13.52%

10%

Does not meet 18/30 month clocks

cinacalcet

Tablet 60 mg (as hydrochloride)

Oral

N

-

-

64.64

13.51%

55.91

64.64

13.51%

10%

Does not meet 18/30 month clocks

cinacalcet

Tablet 90 mg (as hydrochloride)

Oral

N

-

-

96.96

13.51%

83.86

96.96

13.51%

10%

Does not meet 18/30 month clocks

cyproterone

Tablet containing cyproterone acetate 100 mg

Oral

Y

N

Y

51.88

14.28%

44.47

51.88

14.28%

10%

GWAPD

cyproterone

Tablet containing cyproterone acetate 50 mg

Oral

Y

N

Y

13.32

14.28%

11.42

13.32

14.26%

10%

GWAPD

dasatinib

Tablet 100 mg

Oral

N

-

-

3,085.89

12.10%

2,712.50

3,085.89

12.10%

10%

Does not meet 18/30 month clocks

dasatinib

Tablet 20 mg

Oral

N

-

-

1,873.54

12.10%

1,646.84

1,873.54

12.10%

10%

Does not meet 18/30 month clocks

dasatinib

Tablet 50 mg

Oral

N

-

-

3,085.89

12.10%

2,712.50

3,085.89

12.10%

10%

Does not meet 18/30 month clocks

dasatinib

Tablet 70 mg

Oral

N

-

-

3,820.54

12.10%

3,358.25

3,820.54

12.10%

10%

Does not meet 18/30 month clocks

deferasirox

Tablet 180 mg

Oral

N

-

-

212.03

38.46%

130.48

146.19

10.75%

10%

Does not meet 18/30 month clocks

deferasirox

Tablet 360 mg

Oral

N

-

-

424.05

38.46%

260.96

292.38

10.75%

10%

Does not meet 18/30 month clocks

deferasirox

Tablet 90 mg

Oral

N

-

-

106.02

38.46%

65.24

73.10

10.75%

10%

Does not meet 18/30 month clocks

everolimus

Tablet 0.25 mg

Oral

N

-

-

191.76

10.73%

171.18

191.76

10.73%

10%

GWAPD

fenofibrate

Tablet 145 mg

Oral

N

-

-

11.78

28.03%

8.48

9.80

13.47%

10%

GWAPD

fenofibrate

Tablet 48 mg

Oral

N

-

-

7.86

28.03%

5.66

6.54

13.46%

10%

GWAPD

filgrastim

Injection 300 micrograms in 0.5 mL single-use pre-filled syringe

Injection

Y

N

Y

86.27

16.58%

71.97

86.27

16.58%

10%

GWAPD

filgrastim

Injection 480 micrograms in 0.5 mL single-use pre-filled syringe

Injection

Y

N

Y

138.29

16.58%

115.36

138.29

16.58%

10%

GWAPD

gefitinib

Tablet 250 mg

Oral

N

-

-

821.66

43.04%

468.02

821.66

43.04%

10%

GWAPD

hydromorphone

Injection containing hydromorphone hydrochloride 10 mg in 1 mL

Injection

N

-

-

13.43

25.40%

10.02

13.43

25.39%

10%

GWAPD

hydromorphone

Injection containing hydromorphone hydrochloride 2 mg in 1 mL

Injection

N

-

-

10.07

25.40%

7.51

10.07

25.42%

10%

GWAPD

imatinib

Capsule 100 mg (as mesilate)

Oral

Y

N

Y

290.33

27.80%

209.62

290.33

27.80%

10%

GWAPD

imatinib

Capsule 400 mg (as mesilate)

Oral

Y

N

Y

580.65

27.80%

419.23

580.65

27.80%

10%

GWAPD

imatinib

Tablet 100 mg (as mesilate)

Oral

Y

N

Y

290.33

27.80%

209.62

290.33

27.80%

10%

GWAPD

imatinib

Tablet 400 mg (as mesilate)

Oral

Y

N

Y

580.65

27.80%

419.23

580.65

27.80%

10%

GWAPD

lansoprazole

Capsule 30 mg

Oral

Y

N

Y

5.24

14.53%

4.48

5.24

14.50%

10%

GWAPD

lansoprazole

Tablet 30 mg (orally disintegrating)

Oral

Y

N

Y

5.24

14.53%

4.48

5.24

14.50%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 100 mg-25 mg (as monohydrate)-200 mg

Oral

N

-

-

110.74

23.84%

84.34

110.74

23.84%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 125 mg-31.25 mg (as monohydrate)-200 mg

Oral

N

-

-

114.94

23.84%

87.54

114.94

23.84%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 150 mg-37.5 mg (as monohydrate)-200 mg

Oral

N

-

-

121.22

23.84%

92.32

121.22

23.84%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 200 mg-50 mg (as monohydrate)-200 mg

Oral

N

-

-

130.86

23.84%

99.66

130.86

23.84%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 50 mg-12.5 mg (as monohydrate)-200 mg

Oral

N

-

-

100.26

23.84%

76.36

100.26

23.84%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 75 mg-18.75 mg (as monohydrate)-200 mg

Oral

N

-

-

104.87

23.84%

79.87

104.87

23.84%

10%

GWAPD

lurasidone

Tablet containing lurasidone hydrochloride 40 mg

Oral

N

-

-

38.56

28.73%

27.48

38.56

28.73%

10%

GWAPD

lurasidone

Tablet containing lurasidone hydrochloride 80 mg

Oral

N

-

-

77.12

28.73%

54.96

77.12

28.73%

10%

GWAPD

methenamine

Tablet containing methenamine hippurate 1 g

Oral

N

-

-

19.70

13.61%

17.02

19.70

13.60%

10%

Does not meet 18/30 month clocks

moxonidine

Tablet 200 micrograms

Oral

N

-

-

5.67

10.74%

5.06

5.67

10.76%

10%

GWAPD

moxonidine

Tablet 400 micrograms

Oral

N

-

-

9.66

10.74%

8.62

9.66

10.77%

10%

GWAPD

naloxone

Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule

Injection

Y

N

Y

25.27

18.64%

20.56

25.27

18.64%

10%

OWAPD

omeprazole

Capsule 20 mg

Oral

Y

N

Y

4.12

16.61%

4.00

4.12

16.50%

10%

GWAPD

omeprazole

Tablet 20 mg

Oral

Y

N

Y

4.12

16.61%

4.00

4.12

16.50%

10%

GWAPD

omeprazole

Tablet 20 mg (as magnesium)

Oral

Y

N

Y

4.12

16.61%

4.00

4.12

16.50%

10%

GWAPD

oxycodone

Tablet containing oxycodone hydrochloride 40 mg (controlled release)

Oral

Y

N

Y

31.82

13.89%

27.40

31.82

13.89%

10%

GWAPD

oxycodone

Tablet containing oxycodone hydrochloride 80 mg (controlled release)

Oral

Y

N

Y

52.13

13.89%

44.89

52.13

13.89%

10%

GWAPD

pegfilgrastim

Injection 6 mg in 0.6 mL single use pre-filled syringe

Injection

N

-

-

178.18

33.53%

118.44

142.05

16.62%

10%

OWAPD

pemetrexed

Powder for I.V. infusion 100 mg (as disodium)

Injection

Y

N

Y

9.20

16.92%

7.64

9.20

16.96%

10%

OWAPD

pemetrexed

Powder for I.V. infusion 500 mg (as disodium)

Injection

Y

N

Y

45.98

16.92%

38.20

45.98

16.92%

10%

OWAPD

pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Y

N

Y

7.22

14.36%

6.18

7.22

14.40%

10%

GWAPD

pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Y

N

Y

11.11

14.36%

9.51

11.11

14.40%

10%

GWAPD

pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Y

N

Y

14.44

14.36%

12.37

14.44

14.34%

10%

GWAPD

posaconazole

Tablet (modified release) 100 mg

Oral

N

-

-

309.38

43.94%

173.44

201.74

14.03%

10%

Does not meet 18/30 month clocks

pregabalin

Capsule 150 mg

Oral

Y

N

Y

12.66

27.34%

9.20

12.66

27.33%

10%

GWAPD

pregabalin

Capsule 300 mg

Oral

Y

N

Y

18.88

27.34%

13.72

18.88

27.33%

10%

GWAPD

pregabalin

Capsule 75 mg

Oral

Y

N

Y

8.25

27.34%

5.99

8.25

27.39%

10%

GWAPD

raloxifene

Tablet containing raloxifene hydrochloride 60 mg

Oral

Y

N

Y

19.12

18.11%

15.66

19.12

18.10%

10%

GWAPD

rasagiline

Tablet 1 mg (as mesilate)

Oral

N

-

-

69.38

42.90%

39.62

46.18

14.21%

10%

GWAPD

rituximab

Solution for I.V. infusion 100 mg in 10 mL

Injection

N

-

-

67.96

36.38%

43.24

67.96

36.37%

10%

OWAPD

rituximab

Solution for I.V. infusion 500 mg in 50 mL

Injection

N

-

-

339.80

36.38%

216.18

339.80

36.38%

10%

OWAPD

sevelamer

Tablet containing sevelamer carbonate 800 mg

Oral

N

-

-

177.24

10.40%

158.81

177.24

10.40%

10%

Does not meet 18/30 month clocks

sevelamer

Tablet containing sevelamer hydrochloride 800 mg

Oral

N

-

-

177.24

10.40%

158.81

177.24

10.40%

10%

Does not meet 18/30 month clocks

sunitinib

Capsule 12.5 mg

Oral

N

-

-

789.98

10.47%

707.27

789.98

10.47%

10%

Does not meet 18/30 month clocks

sunitinib

Capsule 25 mg

Oral

N

-

-

1,589.93

10.47%

1,423.46

1,589.93

10.47%

10%

Does not meet 18/30 month clocks

sunitinib

Capsule 37.5 mg

Oral

N

-

-

2,382.88

10.47%

2,133.39

2,382.88

10.47%

10%

Does not meet 18/30 month clocks

sunitinib

Capsule 50 mg

Oral

N

-

-

3,219.11

10.47%

2,882.07

3,219.11

10.47%

10%

Does not meet 18/30 month clocks

tacrolimus

Capsule 0.75 mg

Oral

Y

N

Y

187.50

21.26%

147.64

187.50

21.26%

10%

GWAPD

teriflunomide

Tablet 14 mg

Oral

N

-

-

434.72

51.57%

210.53

257.57

18.26%

10%

OWAPD

trastuzumab

Powder for I.V. infusion 150 mg

Injection

N

-

-

237.02

47.79%

123.75

190.80

35.14%

10%

OWAPD

trastuzumab

Powder for I.V. infusion 420 mg

Injection

N

-

-

663.66

47.79%

346.50

534.22

35.14%

10%

OWAPD

trastuzumab

Powder for I.V. infusion 440 mg with diluent

Injection

N

-

-

695.26

47.79%

363.00

420.77

13.73%

10%

OWAPD

trastuzumab

Powder for I.V. infusion 60 mg

Injection

N

-

-

126.10

47.79%

65.84

76.32

13.73%

10%

OWAPD

A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2023 is available in the 2023 April Indicative Combination Flow-on Reductions from Price Disclosure Summary (Excel 14KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.

Indicative prices of brands scheduled for a price disclosure reduction

The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in this cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day.

The indicative prices reports have been replaced by the confirmed prices reports below.

Confirmed prices of brands scheduled for a price disclosure reduction

This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.

The confirmed prices reports are available below.

Brand price reductions and savings to patients

This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 April 2023. This information is made available to assist patients with understanding how much they may save on their PBS medicines.

The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.

The brand price reduction report is available below: